PA
PTGX icon

Parallel Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Parallel Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.5K Sell
118
-5
-4% -$522 ﹤0.01% 2779
2026
Q1 		$13K Buy
123
+14
+13% +$1.24K ﹤0.01% 2639
2025
Q4 		$9.52K Buy
109
+7
+7% +$573 ﹤0.01% 2627
2025
Q3 		$6.78K Buy
102
+5
+5% +$284 ﹤0.01% 2661
2025
Q2 		$5.36K Buy
97
+70
+259% +$3.36K ﹤0.01% 2719
2025
Q1 		$1.31K Hold
27
– – ﹤0.01% 3065
2024
Q4 		$1.04K Sell
27
-16
-37% -$698 ﹤0.01% 3104
2024
Q3 		$1.94K Buy
43
+16
+59% +$646 ﹤0.01% 2899
2024
Q2 		$936 Buy
+27
New +$791 ﹤0.01% 2976

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Parallel Advisors's PTGX Position: Q2 2026 in Review

Parallel Advisors reduced its Protagonist Therapeutics (PTGX) stake by 4.1% in Q2 2026, selling an estimated $522 and leaving 118 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2779.

Parallel Advisors first reported a position in PTGX in Q2 2024 and has held it in 9 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Parallel Advisors held 118 shares of Protagonist Therapeutics worth $14.5K as of Q2 2026.
  • Parallel Advisors sold 5 Protagonist Therapeutics shares in Q2 2026, an estimated $522.
  • Protagonist Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2779 holding.
  • Parallel Advisors first reported a position in Protagonist Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.